Renal Cell Carcinoma CPG Mini Module - Planning Immunotherapy Regiments for Challenging Patient Populations


Renal Cell Carcinoma CPG Mini Module - Planning Immunotherapy Regiments for Challenging Patient Populations​  


The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   


This mini module begins with a case presentation on a patient with metastatic RCC and Crohn's Disease.  Presenter Michael B. Atkins, MD - Georgetown Lombardi Comprehensive Cancer Center addresses the role of anti-PD1 monotherapy for patients with autoimmune conditions or high risk of ipilimumab toxicity as well as data from the HCRN GU16-260 study.  Dr. Atkins also discusses when to stop RCC therapy, using melanoma treatment as a model.  The mini module concludes with a panel discussion of factors to consider when discontinuing IO/TKI combination therapy and when re-starting immunotherapy in the event of RCC recurrence.

Run time: 12 minutes


Target Audience 

Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 


SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 


The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021). 
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts. 

Video Presentation
Individual topic purchase: Selected
Renal Cell Carcinoma CPG Mini Module - Planning Immunotherapy Regimens for Challenging Patient Populations